A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KN019 in Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Belatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 08 Nov 2019 Status changed from not yet recruiting to recruiting.
- 10 Dec 2018 New trial record
- 16 Nov 2018 According to an Alphamab Oncology media release, the company expects to initiate this trial in 1H 2019.